. 2018 Nov 16;18:581. doi: 10.1186/s12879-018-3463-4

Table 1.

Overview of included studies examining the efficacy, effectiveness, and adherence of oral PrEP

Characteristics									Number of incident HIV infections
Year	Study name	Geographical location	Population	Sample size	Total follow-up time (person-years)	Design	Regimen	Drug	Study drug	Placebo/ comparator	Total
2010	iPrEx [6]	Global	MSM/TGW	2499	3324	RDBPCT	Daily	TDF-FTC	36	64	100
2012	Partners study [7]	Kenya and Uganda	Heterosexual HIV-discordant couples	4758	7820	RDBPCT	Daily	TDF-FTC	13	52	82
2012	Partners study [7]	Kenya and Uganda	Heterosexual HIV-discordant couples	4758	7820	RDBPCT	Daily	TDF	17	52	82
2012	TDF2 [8]	Botswana	Heterosexual	1219	1563	RDBPCT	Daily	TDF-FTC	9	24	33
2012	FEM-PrEP [13]	Kenya, Tanzania and South Africa	Heterosexual females	2120	–	RDBPCT	Daily	TDF-FTC	33	35	68
2012	Kenya safety and adherence study [38]	Kenya	MSM and Female sex workers	72	–	RDBPCT	Daily	TDF-FTC	0	1	1
2012	Kenya safety and adherence study [38]	Kenya	MSM and Female sex workers	72	–	RDBPCT	Time-driven	TDF-FTC	0	1	1
2013	Partners adherence substudy [17]	Kenya and Uganda	Heterosexual HIV-discordant couples	1147	807	Convenience sub-cohort of a RDBPCT	Daily	TDF-FTC	0	14	14
2013	Partners adherence substudy [17]	Kenya and Uganda	Heterosexual HIV-discordant couples	1147	807	Convenience sub-cohort of a RDBPCT	Daily	TDF	0	14	14
2013	Bangkok tenofovir study [31]	Bangkok	PWID	2413	9665	RDBPCT	Daily	TDF	17	33	50
2013	Uganda safety and adherence study [35]	Uganda	Heterosexual HIV-discordant couples	72	–	RDBPCT	Daily	TDF-FTC	0	0	0
2013	Uganda safety and adherence study [35]	Uganda	Heterosexual HIV-discordant couples	72	–	RDBPCT	Time-driven	TDF-FTC	0	0	0
2013	ATN 082 (Project PrEPARE) [54]	United States	Young MSM	58	–	RBPCT	Daily	TDF-FTC	0	0	0
2013	ATN 082 (Project PrEPARE) [54]	United States	Young MSM	58	–	RBPCT	Daily	No pill	0	0	0
2014	iPrEx extension [15]	Global	MSM/TGW	1603 (1225 received)	–	Open Label	Daily	TDF-FTC	28	13	41
2015	VOICE [14]	South Africa, Uganda, Zimbabwe	Heterosexual females	3019	4253	RCT	Daily	TDF-FTC	61	60	173
2015	VOICE [14]	South Africa, Uganda, Zimbabwe	Heterosexual females	3019	4253	RCT	Daily	TDF	52	60	173
2015	HPTN 067/ADAPT^a [36]	South Africa	Heterosexual females	191	–	RCT with different regimens as comparators	Daily	TDF-FTC	1	N/A	5
							Time-driven		2
							Event-driven		2
2015	Generating adherence Philadelphia [50]	United States	Young MSM of colour	23	7.5	Observational	Daily	TDF-FTC	0	N/A	0
2015	PROUD [9]	United Kingdom	MSM	544	465	RCT with a 1 year deferred group as comparator	Daily	TDF-FTC	3	20	23
2015	IPERGAY [10]	France and Canada	MSM/TGW	400	431	RDBPCT	Event-driven	TDF-FTC	2	14	16
2016	Bangkok MSM^a [55]	Thailand	MSM /TGW	168	–	Observational	Daily	TDF-FTC	0	N/A	0
2016	Permanente Cohort [24]	USA	At-risk	972	850	Open label	Daily	TDF-FTC	0	2 Off-PrEP	2
2016	The Demo Project [23]	USA	MSM/TGW	557	481	Open label	Daily	TDF-FTC	1	1 Off-PrEP	2
2017	SPARK^a [57]	United States	MSM	301	–	Open Label	Daily	TDF-FTC	–	–	–
2017	IPERGAY extension [22]	France/Canada	MSM/TGW	361	518	Open label	Event-driven	TDF-FTC	0	1 Off-PrEP	1
2017	Short term PrEP Mozambique^a [25]	Mozambique	Heterosexual females	74	7.4	Open label	Daily	TDF-FTC	0	N/A	1
2017	Parisian MSM^a [26]	France	MSM	785	215	Open label	Daily & Event-driven	TDF-FTC	3	N/A	3
2017	PRELUDE^a [27, 28]	Australia	Gay/bisexual males	317	381	Open label	Daily	TDF-FTC	0	N/A	0
2017	PROUD adherence^a [29]	UK	MSM	544 enrolled (481 initiated)	1253	Open label	Daily	TDF-FTC	10	N/A	10
2017	Pluspills^a [30]	South Africa	Adolescents	148	131	Open label	Daily	TDF-FTC	0	1 Off-PrEP	1
2017	Brazil Demo^a [65]	Brasil	MSM/TGW	450	389	Open label	Daily	TDF-FTC	0	2 Off-PrEP	2

^a Abstract available only. MSM men who have sex with men, TGW transgender women, PWID people who inject drugs, RCT randomised controlled trial, RDBPCT randomised, double blinded, placebo controlled trial, TDF tenofovir, FTC emtricitabine